+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID03013998

Master Protocol for Genomic-Based Personalized Treatment of Acute Myeloid Leukemia Using Multiple Targeted Therapies

Led by Beat AML, LLC · Updated on 2026-09-03

3000

Participants Needed

31

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating a multi-sub-study clinical trial called the Beat AML Master Protocol, focused on biomarker-based treatment for acute myeloid leukemia AML. This Phase 1b23 trial aims to develop a genomic screening method to assign patients to various sub-studies based on the specific AML subtype or other myeloid malignancies. The goal is to evaluate different investigational therapies or combinations to advance targeted treatments for approval. Participants may receive different treatments depending on their assigned sub-study, including investigational drugs like SNDX-5613, venetoclax combined with azacitidine, ZE46-0134, ficlatuzumab, samalizumab, BI 836858, AG-221, entospletinib, pevonedistat, AZD5153, gilteritinib, and others. Treatment schedules vary widely, with dosing cycles ranging from continuous daily oral medications to intravenous infusions on specific days within 28-day cycles. Some studies include dose escalation followed by expansion phases, and treatment may continue until disease progression, unacceptable toxicity, or other protocol-defined criteria. Participants will undergo genomic and biomarker testing to guide treatment assignment within the protocol. They will have regular visits for treatment administration, safety monitoring, disease response evaluation, and laboratory assessments. Outcome measures include the proportion of patients completing biomarker studies within 7 days, assignment to targeted therapies, clinical response rates, event-free survival, overall survival, and quality of life assessments, with follow-up extending up to several years. The trial involves complex monitoring of safety and efficacy to better understand and improve AML treatment options.

CONDITIONS

Brief Title

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Research Team

A

Ashley Yocum, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here